Introduction

Taj Pharma India Ltd is a globally recognized pharmaceutical manufacturer headquartered in Sarigam, Gujarat, with more than 30 years of experience in producing, exporting, and supplying high-quality medicines to global markets. The company’s robust portfolio, extensive manufacturing infrastructure, and deep regulatory expertise position it to expand into the Eurasian Economic Union (EAEU) — a market comprising Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan — while managing the registration and export process from India.

Why the EAEU and What It Means for Taj Pharma

The EAEU offers a harmonised regulatory framework for pharmaceutical products, enabling a single registration to grant access to all member states. This integrated market is attractive due to its large patient population, substantial healthcare demand, and reliance on imported high-quality generics and specialty drugs. To enter this market, foreign manufacturers must register medicinal products and obtain plant compliance approvals via a local Authorized Representative within an EAEU member state. Once registered, products can be marketed across all EAEU countries.

Taj Pharma’s Regulatory Pathway into the EAEU

1. Appoint a Local Authorized Representative

Taj Pharma will engage a local regulatory partner/authorized representative based in Kazakhstan — one of the preferred reference states for EAEU registration — to act as the legal entity responsible for submissions and ongoing regulatory communication.

2. Prepare a Unified EAEU Dossier

Regulations require a Common Technical Document (CTD) compliant dossier with modules covering quality, safety, efficacy, labeling, and manufacturing details. Key steps include:

  • Full translation of required sections into Russian.
  • Alignment with EAEU pharmacopeial and labeling standards.
  • Demonstrating GMP compliance of the Indian manufacturing site.

3. EAEU GMP Certification

Although Taj Pharma’s Indian facility already complies with WHO-GMP, ISO, GLP standards and aims for EU-GMP certification, achieving EAEU-recognized GMP certification is essential before or during product registration submissions.

4. Submission and Approval

The authorized representative will submit the dossier to the regulatory authority in Kazakhstan. After evaluation and response to queries, approvals can be granted in an estimated 9–18 months, followed by mutual recognition across other EAEU nations.

Taj Pharma’s EAEU Product Portfolio — Therapeutic Categories & Key Medicines

Taj Pharma manufactures a broad and export-ready range of pharmaceutical products across multiple therapeutic segments. The table below highlights key products suitable for registration in the EAEU:

Therapeutic CategoryProduct Name / Dosage FormIndication / Use
Oncology & CytotoxicCytarabine Injection BP 2 g / 500 mgAntineoplastic chemotherapy for leukemia
Antibiotics & Anti-InfectivesTigecycline Injection 50 mgBroad-spectrum antibiotic for severe infections
Antibiotics (Injection)Ampicillin Injection 500 mgBroad-spectrum antibiotic for bacterial infections
Anti-TB TherapyRifampicin + Isoniazid + Ethambutol TabletsFixed-dose combination for tuberculosis
CNS & NeurologyLevetiracetam Tablets 250 mg / 1000 mgAntiepileptic for seizure disorders
Cardiovascular & DiureticsChlorthalidone Tablets 25 mgDiuretic for hypertension & edema
AntimalarialMefloquine HCl 250 mgTreatment & prevention of malaria
Respiratory/BronchodilatorTheophylline Prolonged-Release 200 mgAsthma & COPD therapy
Specialty BiologicsHuman Coagulation Factor VIII 500 IUHemophilia A treatment
PDE-5 InhibitorsUdenafil Tablets 100 mgTreatment for erectile dysfunction and related conditions

Products subject to EAEU compliance, translation, and submission readiness.

Strategic Advantages Taj Pharma Brings to the EAEU

1. Global Experience & Export Legacy

With decades serving markets in Africa, the Middle East, CIS, Latin America, and Asia, Taj Pharma brings deep supply-chain experience, robust documentation practices, and regulatory know-how — a crucial advantage for navigating EAEU registration complexities.

Bedaquiline Tablets 100mg Manufacturer in Mumbai Bedaquiline Tablets 100mg Manufacturer Vapi, Gujarat
Bedaquiline Tablets 100mg (Hensen)- Open for EAEU registrations

2. WHO-GMP & International Manufacturing Standards

Taj Pharma’s facilities are WHO-GMP certified, and the company is advancing towards PICS and EU-GMP compliance, ensuring products meet stringent global quality and safety standards — a strong foundation for EAEU regulators.

3. Diverse Dosage Forms & Capacities

The company produces tablets, capsules, injectables, effervescent tablets, oral jellies, creams/ointments, and sachets — with high monthly production capacities, making it capable of serving large healthcare markets efficiently.

Impact on EAEU Healthcare Systems

The introduction of Taj Pharma’s medicines into the EAEU would have several positive effects:

Expanded Access to High-Quality Generics

The EAEU has a growing demand for affordable, WHO-GMP compliant generics, especially in chronic and infectious disease segments. Taj Pharma’s portfolio can address therapy gaps and improve treatment availability.

Enhanced Supply Chain Reliability

Leveraging Taj Pharma’s export-oriented supply chain can reduce medicine shortages and provide stable delivery channels for essential drugs.

Cost-Effective Healthcare Solutions

By offering therapeutically equivalent but cost-competitive products, healthcare systems can optimize budgets without compromising patient outcomes.

Elevated Collaboration & Local Manufacturing Synergies

Taj Pharma’s engagement with local partners and distributors fosters knowledge transfer, regulatory alignment, and potential future collaboration on regional manufacturing initiatives.

Registering Taj Pharma’s products and manufacturing capabilities in the EAEU through a local representative in Kazakhstan is a strategically sound move with the potential to significantly improve healthcare delivery across EAEU nations. With a diverse product range, global compliance readiness, and decades of export experience, Taj Pharma stands to become a trusted healthcare partner within the EAEU, driving access to quality medicines and strengthening healthcare resilience throughout the region.

Together, through collaboration, compliance, and compassion, we can transform regulatory opportunity into real-world healing.

For partnership, product registration, or inspection inquiries:
Sales@tajpharmaindia.com I Info@tajpharma.com

Sales:+91-7861865490 / 9004444031

24/7: +91 84484 44095 / 8071 555 357

Mumbai Office: +91 22 6973 8917

WhatsApp:+91-74 0000 9975 / 76
www.tajpharma.in | www.tajgenerics.com | www.tajpharma.com